Vienna — The investigational monoclonal antibody trevogrumab was associated with lean mass preservation and greater loss of fat mass in people taking semaglutide, an interim trial data showed.
Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model. Elevai believes that EL-32 has the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback